Kala Pharmaceuticals to Present at Two Upcoming Investor Conferences in September
August 29 2019 - 8:00AM
Business Wire
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical
company focused on the development and commercialization of
therapeutics using its proprietary AMPPLIFY™ mucus-penetrating
particle (MPP) Drug Delivery Technology, today announced that
members of its management team will participate in the following
upcoming conferences in September:
2019 Wells Fargo Healthcare Conference Date: Thursday,
September 5, 2019 Fireside Chat Time: 8:00 a.m. Location: Boston,
MA
H.C. Wainwright 21st Annual Global Investment Conference
Date: Tuesday, September 10, 2019 Presentation Time: 10:50 a.m.
Location: New York, NY
To access a live webcast and subsequent archived recording of
the presentations, please visit the “Investors & Media” section
on the Kala website at http://kalarx.com
About Kala Pharmaceuticals, Inc.
Kala is a biopharmaceutical company focused on the development
and commercialization of therapeutics using its proprietary
AMPPLIFY™ mucus-penetrating particle (MPP) Drug Delivery
Technology, with an initial focus on the treatment of eye diseases.
Kala has applied the AMPPLIFY Drug Delivery Technology to a
corticosteroid, loteprednol etabonate (LE), designed for ocular
applications, resulting in the August 2018 FDA approval of
INVELTYS® for the treatment of inflammation and pain following
ocular surgery and its lead product candidate, KPI-121 0.25%, for
the temporary relief of the signs and symptoms of dry eye
disease.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190829005004/en/
Investors: Hannah Deresiewicz
hannah.deresiewicz@sternir.com 212-362-1200
or
Media: Kari Watson kwatson@macbiocom.com 781-235-3060
KALA BIO (NASDAQ:KALA)
Historical Stock Chart
From May 2024 to Jun 2024
KALA BIO (NASDAQ:KALA)
Historical Stock Chart
From Jun 2023 to Jun 2024